Indications and uses
helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun
SHISEIDO THE MAKEUP LIFTING FOUNDATION
- Manufacturer
- SHISEIDO AMERICA INC. | Davlyn Industries Inc
- Effective date
- 2012-07-06
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:46:47
Label at a glance#
ProductSHISEIDO THE MAKEUP LIFTING FOUNDATION I00
Active ingredientOCTINOXATE, TITANIUM DIOXIDE
Label structure20 sections
Dosage and administration
For sunscreen use: apply liberally 15 minutes before sun exposure use a water resistant sunscreen if swimming or sweating reapply at least every 2 hours Sun Protection Measures . Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: limit time in the su...
Storage and handling
protect this product in this container from excessive heat and direct sun.
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
OTC - ACTIVE INGREDIENT SECTION
OTC - PURPOSE SECTION
| Active ingredient | Purpose |
|---|---|
| OCTINOXATE 2.9% | Sunscreen |
| TITANIUM DIOXIDE 4.4% | Sunscreen |
Uses
- helps prevent sunburn
- if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun
Warnings
OTC - DO NOT USE SECTION
For external use only
Do not use on damaged or broken skin
OTC - WHEN USING SECTION
When using this product keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
Stop use and ask a doctor if rash occurs
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away.
Directions
For sunscreen use:
- apply liberally 15 minutes before sun exposure
- use a water resistant sunscreen if swimming or sweating
- reapply at least every 2 hours
- Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including:
- limit time in the sun, especially from 10 a.m. – 2 p.m.
- wear long-sleeve shirts, pants, hats, and sunglasses
- children under 6 months: Ask a doctor
Inactive Ingredients
WATER, GLYCERIN, CYCLOMETHICONE, DIMETHICONE, BUTYLENE GLYCOL, SQUALANE, HYDROGENATED POLYDECENE, PEG-10 DIMETHICONE, DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER, POLYMETHYLSILSESQUIOXANE, DIATOMACEOUS EARTH, DISTEARDIMONIUM HECTORITE, SODIUM HYALURONATE, PEG/PPG-14/7 DIMETHYL ETHER, ISOSTEARIC ACID, ALUMINA, POLYSILICONE-2, TRIETHOXYCAPRYLYLSILANE, PEG-150, HYDROGEN DIMETHICONE, TOCOPHEROL, SORBITAN SESQUIISOSTEARATE, BHT, PHENOXYETHANOL, METHYLPARABEN, FRAGRANCE, TITANIUM DIOXIDE, IRON OXIDES,
Other information
- protect this product in this container from excessive heat and direct sun.
Questions or comments?
Call toll free 1-800-906-7503
SPL UNCLASSIFIED SECTION
SHISEIDO AMERICA INC.
NEW YORK, N.Y. 10022
SHISEIDO DIST.
NEW YORK • PARIS • MILANO
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - B 20
SHISEIDO
B 20
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - B 40
SHISEIDO
B 40
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - B 60
SHISEIDO
B 60
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - I 00
SHISEIDO
I 00
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - I 20
SHISEIDO
I 20
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - I 40
SHISEIDO
I 40
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - I 60
SHISEIDO
I 60
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - O 20
SHISEIDO
O 20
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - O 40
SHISEIDO
O 40
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - O 60
SHISEIDO
O 60
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 30mL Tube Carton - O 80
SHISEIDO
O 80
The Makeup
Lifting Foundation
Lustrous Finish
BROAD SPECTRUM
SPF 17
sunscreen
30mL NET WT. 1.1 OZ.
FDA-Initiated Inactive NDC Indexing#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| OCTINOXATE | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| TITANIUM DIOXIDE | ACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| OCTINOXATE | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| TITANIUM DIOXIDE | ACTIVE MOIETY | 15FIX9V2JP | 1 | |
| ALUMINUM OXIDE | INACTIVE INGREDIENT | LMI26O6933 | 1 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 1 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| CYCLOMETHICONE | INACTIVE INGREDIENT | NMQ347994Z | 1 | |
| DIATOMACEOUS EARTH | INACTIVE INGREDIENT | 2RF6EJ0M85 | 1 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 1 | |
| FERRIC OXIDE YELLOW | INACTIVE INGREDIENT | EX438O2MRT | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| HYALURONATE SODIUM | INACTIVE INGREDIENT | YSE9PPT4TH | 1 | |
| HYDROGENATED POLYDECENE (550 MW) | INACTIVE INGREDIENT | U333RI6EB7 | 1 | |
| ISOSTEARIC ACID | INACTIVE INGREDIENT | X33R8U0062 | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| PEG-10 DIMETHICONE (600 CST) | INACTIVE INGREDIENT | 8PR7V1SVM0 | 1 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| POLYETHYLENE GLYCOL 7000 | INACTIVE INGREDIENT | Q0JET65GEL | 1 | |
| POLYMETHYLSILSESQUIOXANE (4.5 MICRONS) | INACTIVE INGREDIENT | 59Z907ZB69 | 1 | |
| SQUALANE | INACTIVE INGREDIENT | GW89575KF9 | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| TOCOPHEROL | INACTIVE INGREDIENT | R0ZB2556P8 | 1 | |
| TRIETHOXYCAPRYLYLSILANE | INACTIVE INGREDIENT | LDC331P08E | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- SHISEIDO THE MAKEUP LIFTING FOUNDATION I00
- OCTINOXATE and TITANIUM DIOXIDE
- OCTINOXATE
- TITANIUM DIOXIDE
- WATER
- CYCLOMETHICONE
- GLYCERIN
- DIMETHICONE
- BUTYLENE GLYCOL
- SQUALANE
- HYDROGENATED POLYDECENE (550 MW)
- PEG-10 DIMETHICONE (600 CST)
- POLYMETHYLSILSESQUIOXANE (4.5 MICRONS)
- DIATOMACEOUS EARTH
- ISOSTEARIC ACID
- ALUMINUM OXIDE
- PHENOXYETHANOL
- METHYLPARABEN
- TRIETHOXYCAPRYLYLSILANE
- POLYETHYLENE GLYCOL 7000
- TOCOPHEROL
- BUTYLATED HYDROXYTOLUENE
- HYALURONATE SODIUM
- FERRIC OXIDE RED
- FERRIC OXIDE YELLOW
- SHISEIDO THE MAKEUP LIFTING FOUNDATION I20
- SHISEIDO THE MAKEUP LIFTING FOUNDATION I40
- SHISEIDO THE MAKEUP LIFTING FOUNDATION I60
- SHISEIDO THE MAKEUP LIFTING FOUNDATION B20
- SHISEIDO THE MAKEUP LIFTING FOUNDATION B40
- SHISEIDO THE MAKEUP LIFTING FOUNDATION B60
- SHISEIDO THE MAKEUP LIFTING FOUNDATION O20
- SHISEIDO THE MAKEUP LIFTING FOUNDATION O40
- SHISEIDO THE MAKEUP LIFTING FOUNDATION O60
- SHISEIDO THE MAKEUP LIFTING FOUNDATION O80
NDC Codes#
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION / INTRAVENOUS | NA | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, CHEWABLE / ORAL | 2 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GUM, CHEWING / BUCCAL | 5 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| DIATOMACEOUS EARTH | DIATOMACEOUS EARTH | 2RF6EJ0M85 | SOAP / TOPICAL | 0.27 %w/w | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, COATED / ORAL | 1 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CAPSULE, LIQUID FILLED / ORAL | 0.1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ELIXIR / ORAL | 800 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SPRAY / TOPICAL | 3 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / ORAL | 3822 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED PELLETS / ORAL | 4.4 mg | ||
| SQUALANE | SQUALANE | GW89575KF9 | CREAM / TOPICAL | 6 %w/w | ||
| ISOSTEARIC ACID | ISOSTEARIC ACID | X33R8U0062 | GEL / TOPICAL | 20 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING / ORAL | 6 mg | ||
| TOCOPHEROL | TOCOPHEROL | R0ZB2556P8 | INJECTION, EMULSION / INTRAVENOUS | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ENEMA / RECTAL | 0.18 %w/v | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SOLUTION / TOPICAL | 3 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | LOTION / TOPICAL | 1000 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | FILM / BUCCAL | 0.27 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUSPENSION / ORAL | 113 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | CREAM / TOPICAL | 57 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | OINTMENT / TOPICAL | 29 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / VAGINAL | 0.1 %w/w | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL / TOPICAL | 1.05 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / EPIDURAL | 1 mg | ||
| TOCOPHEROL | TOCOPHEROL | R0ZB2556P8 | CAPSULE / ORAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE / ORAL | 55 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / ORAL | 388 mg | ||
| DIATOMACEOUS EARTH | DIATOMACEOUS EARTH | 2RF6EJ0M85 | CAPSULE / ORAL | 3.4 mg | ||
| DIATOMACEOUS EARTH | DIATOMACEOUS EARTH | 2RF6EJ0M85 | CAPSULE, EXTENDED RELEASE / ORAL | 5 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / OPHTHALMIC | 0.05 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IRRIGATION | 2 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, EXTENDED RELEASE / ORAL | 0.17 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER, FOR SOLUTION / ORAL | 126 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, ORALLY DISINTEGRATING / ORAL | 2 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE, DELAYED RELEASE / ORAL | 3 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / TOPICAL | 0.16 %w/w | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, ORALLY DISINTEGRATING / ORAL | 2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SOLUTION / ORAL | 14 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / NASAL | 250 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER, FOR SUSPENSION / ORAL | 297 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | LOTION / TOPICAL | 0.01 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET / ORAL | 1.8 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAMUSCULAR | 23 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAVITREAL | 23 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / RECTAL | 1808 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a745b082-532f-4929-89de-19e108c99155 | eb917f94-fee4-452e-89b1-80564ddd1f25 | 2023-10-23 | Warnings | eb917f94-fee4-452e-89b1-80564ddd1f25 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.